- Medicenna Therapeutics Corp. (MDNA) has been issued a patent by the U.S. Patent and Trademark Office (USPTO)
- The patent is titled “Interleukin-4 Receptor-Binding Fusion Proteins And Uses Thereof”
- The patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered Superkines
- The above patent expands on Medicenna’s Empowered Superkine Platform with three other issued patents related to the delivery of Bcl-2 proteins via IL4/IL13 receptors
- Medicenna is a clinical-stage immunotherapy company
- Medicenna Therapeutics Corp. was unchanged at $1.14 at 10:18 AM ET
Medicenna Therapeutics (MDNA) has been issued a U.S. patent titled “Interleukin-4 Receptor-Binding Fusion Proteins And Uses Thereof.”
The patent provides intellectual property (IP) protection for methods of treating degenerative diseases via the administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family polypeptide.
The patent’s term extends into at least 2038 without accounting for any potential extensions.
“This latest patent strengthens our IP protection, diversifies our pipeline while underscoring the versatility of the Superkine platform,” stated Dr. Fahar Merchant, President and CEO of Medicenna.
“By utilizing directed evolution, the Superkine platform creates highly selective tunable cytokines that can be seamlessly integrated with a variety of additional therapeutic moieties,” he added.
Increased programmed cell death, or apoptosis, is linked to the progression of a variety of degenerative diseases such as Alzheimer’s disease, Parkinson’s disease, stroke, muscular dystrophy, spinal cord injury and others.
Medicenna’s IL-4/IL-13 Superkine empowered with Bcl-2 family of fusion proteins are designed to treat these and other degenerative diseases by delivering anti-apoptotic peptides to cells expressing IL-4 and IL-13 receptors.
The patent expands on Medicenna’s Empowered Superkine Platform with three other patents related to the delivery of Bcl-2 proteins via IL4/IL13 receptors (US Patent No. 10,106,592, US Patent No. 11,352,402, Japanese Patent No. 6661530).
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines.
Medicenna Therapeutics Corp. was unchanged at $1.14 at 10:18 AM ET.
